Anti-viral Immunity in the Tumor Microenvironment: Implications for the Rational Design of Herpes Simplex Virus Type 1 Oncolytic Virotherapy

被引：0
|
作者：
Paul J. F. Rider
Ifeanyi K. Uche
Larissa Sweeny
Konstantin G. Kousoulas
机构：
[1] Louisiana State University,Division of Biotechnology and Molecular Medicine and Department of Pathobiological Sciences, School of Veterinary Medicine
[2] Louisiana State University Health Sciences Center,undefined
来源：
Current Clinical Microbiology Reports | 2019年 / 6卷
关键词：
HSV; Oncolytic; Herpesvirus; VC2;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：193 / 199
页数：6
相关论文
共 50 条
  • [1] Anti-viral Immunity in the Tumor Microenvironment: Implications for the Rational Design of Herpes Simplex Virus Type 1 Oncolytic Virotherapy
    Rider, Paul J. F.
    Uche, Ifeanyi K.
    Sweeny, Larissa
    Kousoulas, Konstantin G.
    CURRENT CLINICAL MICROBIOLOGY REPORTS, 2019, 6 (04) : 193 - 199
  • [2] The 16th International Oncolytic Virus Conference: Advancing oncolytic virotherapy by balancing anti-tumor and anti-viral immunity
    Stavrakaki, Eftychia
    Everts, Anne
    van den Hoogen, Bernadette G.
    Lamfers, Martine L. M.
    MOLECULAR THERAPY ONCOLOGY, 2025, 33 (01):
  • [3] The tumor immunologic microenvironment influences antitumor efficacy of oncolytic herpes simplex virotherapy
    Leddon, Jennifer L.
    Chen, Chun-Yu
    Currier, Mark
    Wang, Pin-Yi
    Jung, Francesca
    Cripe, Kevin
    Haworth, Kellie
    Eubank, Timothy
    Hildeman, David
    Cripe, Timothy
    CANCER RESEARCH, 2014, 74 (20)
  • [4] Evolution of anti-viral and anti-tumor immunity in tumors in response to oncolytic virus therapy
    Lyudovyk, Olga
    Burman, Bharat
    Ceglia, Nicholas
    Greenbaum, Benjamin
    Elhanati, Yuval
    Zamarin, Dmitriy
    CANCER RESEARCH, 2024, 84 (07)
  • [5] The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment
    Uche, Ifeanyi Kingsley
    Kousoulas, Konstantin G.
    Rider, Paul J. F.
    VIRUSES-BASEL, 2021, 13 (07):
  • [6] ONCOLYTIC VIROTHERAPY FOR OSTEOSARCOMA WITH HERPES SIMPLEX VIRUS TYPE 1 MUTANT HF10
    Kohno, Shin-Ichi
    Chiwata, Eri
    Toshitsuna, Shiho
    Mineno, Junichi
    Nishiyama, Yukihiro
    JOURNAL OF GENE MEDICINE, 2014, 16 (7-8): : 245 - 245
  • [7] THE ANTI-VIRAL EFFECT OF TUNICAMYCIN ON HERPES-SIMPLEX VIRUS
    KATZ, E
    MARGALITH, E
    DUKSIN, D
    ISRAEL JOURNAL OF MEDICAL SCIENCES, 1980, 16 (06): : 484 - 485
  • [8] ANTI-VIRAL ACTIVITY OF TUNICAMYCIN ON HERPES-SIMPLEX VIRUS
    KATZ, E
    MARGALITH, E
    DUKSIN, D
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1980, 17 (06) : 1014 - 1022
  • [9] ANTI-VIRAL ACTIVITY OF ANTI-LIPIDEMIC COMPOUNDS ON HERPES-SIMPLEX VIRUS TYPE-1
    MEHL, JK
    WITIAK, DT
    HAMPARIAN, VV
    HUGHES, JH
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1980, 18 (02) : 269 - 275
  • [10] A comparison of the anti-viral efficacy of murine type IIFN transgenes against herpes simplex virus type 1
    Carr, DJJ
    Haerle, P
    AgBaga, MP
    Cull, V
    Lawson, C
    JOURNAL OF LEUKOCYTE BIOLOGY, 2001, : 37 - 37
12345